Pharmacopeia to acquire Eos

PCOP will acquire genomics toolkit play Eos Biotechnology (South San Francisco, Calif.) in a stock deal valued at $197 million, based on PCOP's close on Tuesday at $18.51. The deal value includes Eos' $44 million in cash. The deal combines Eos' target identification and validation technologies and antibody development platform with PCOP's small molecule discovery capabilities. ...